We have recently developed a new melanoma vaccine clinical trial testing immunization with three full length melanoma tumor antigens (HAdV-5 TMM2, encoding Tyrosinase, MART-1 and MAGE-A6), instead of a single antigen [24], as in our previous trial [6]. Here, MLANA is linked to melanoma.